HOME >> BIOLOGY >> NEWS
Proteins may help identify patients who will respond better to treatments in certain cancers

Scientists today presented studies of proteomic and genomic markers that could help oncologists devise better treatment approaches for specific patients, and may improve clinical outcomes. The studies were presented here today at the International Conference on Molecular Targets and Cancer Therapeutics organized by the American Association of Cancer Research (AACR), National Cancer Institute (NCI) and European Organisation for Research and Treatment of Cancer (EORTC).

Molecular marker expression phenotype is an independent prognostic factor for outcome in the chart head and neck cancer randomized trial: Abstract 733

A clinical study of head and neck cancer patients found that molecular markers -- the proteins that distinguish specific tumors -- allowed doctors to identify patients who would respond better to radiotherapy than others. Investigators looked at molecular marker expression profiles in 402 patients with head and neck squamous cell carcinoma. The study focused on biological factors such as vascular density and the expression of proteins involved in the regulation of cell cycle progression, proliferation, or apoptosis (programmed cell death), which are known to affect the way that a tumor responds to radiotherapy.

"We are using new strategies for data analysis to exploit the potential of molecular markers," said Francesca Buffa, PhD, of the Gray Cancer Institute in London. "We hope that by tailoring cancer therapy to the biological behavior of an individual patient's tumor, we will be able to improve the success of radiotherapy and provide increased clinical benefits to the patients," she added.

Eight distinct groups of tumors, each with similar biological profiles, were identified within the patient group. Drs. Buffa, Soren Bentzen and their colleagues looked at whether it was possible to predict the outcome of radiotherapy based on these molecular profiles, when compared to more traditional characteristics such as t
'"/>

Contact: Warren Froelich
froelich@aacr.org
215-440-9300
American Association for Cancer Research
19-Nov-2003


Page: 1 2 3

Related biology news :

1. Proteins show promise for mosquito control
2. Proteins transform DNA into molecular velcro
3. Proteins enable HIV to override cells defenses
4. New Science Press launches Proteins: From Sequence to Structure
5. Report: Proteins can be engineered as widely adaptable bioelectronic sensors
6. Proteins in African HIV strains interact differently with drugs
7. Proteins are vastly more complicated than previously realized
8. Life and death struggle: Proteins play against each other, bringing balance to immune system
9. Proteins that bind to sperm offer clues to male fertility and possible male contraception
10. Scientists Show Proteins Function Individually As Part Of DNA Repair
11. Genes Found That Label Cell Proteins For Disposal

Post Your Comments:
(Date:8/12/2015)... , Aug. 12, 2015   MedNet Solutions ... the entire spectrum of clinical research, is proud to ... the company,s comprehensive SaaS-based eClinical technology platform, has led ... the first two quarters of 2015.   Q2 2015 ... largest quarters measured by contract value sold in the ...
(Date:8/12/2015)... Aug. 12, 2015  New research unveiled at ... Android phones to steal users, fingerprints. Information released ... of fingerprint scanners on mobile devices, making the ... secure biometrics on mobile devices, HYPR Corp. recently ... convenient authentication systems with strong cryptographic security. More ...
(Date:8/11/2015)... -- Today, ZUK announced its Android smartphone Z1, featuring ... revenues in 2015 that relate to sales of FPC1155 for this ... 2,200 MSEK for 2015. Jörgen Lantto, CEO of FPC, ... smartphone manufacturer in China and we ... 155 for Z1 , ...
Breaking Biology News(10 mins):MedNet Solutions Experiences Explosive Corporate Growth 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 3FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2
(Date:8/27/2015)... GlassesOff (OTCBB: GLSO), a visual neuroscience technology company ... system, announced today a partnership with eight-time All-Star, ... to develop a new mobile app designed for professional and ... performance. Vision is the inception of every move ... or blocking a pass. The critical impact vision speed has ...
(Date:8/26/2015)... ... August 26, 2015 , ... MediVet Biologics, a leader in ... is to open in Manhattan, Kansas in early October, 2015. The location of ... research and development through collaboration with researchers from Kansas State University’s College of ...
(Date:8/26/2015)... , Aug. 26, 2015  Platform therapeutic company ... has received a $1.5M Phase II SBIR grant ... further develop its therapeutic agent to reduce arteriovenous ... in end stage renal disease (ESRD) patients undergoing ... Institute of Diabetes and Digestive and Kidney Diseases ...
(Date:8/26/2015)... 26, 2015 Despite recent ... the optimism in biotech,s forecast is the recent ... sciences advancements.  Active biotechnology & healthcare companies with ... (OTCQB: PBIO), Sequenom, Inc. (NASDAQ: SQNM ), ... Pharmaceutical Corp. (NASDAQ: RPTP ) and EnteroMedics ...
Breaking Biology Technology:Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 2Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 3MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 3Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 2New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 3New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 4New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 5New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 6New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 7
Cached News: